CINJ 070501(NJ 1205): A Phase II Study of Imatinib Mesylate and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2014
At a glance
- Drugs Imatinib (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 17 Nov 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 17 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Jul 2009 Additional lead trial investigators identified as reported by New Jersey Cancer Trial Connect record.